500 related articles for article (PubMed ID: 26382310)
1. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
Menopause; 2015 Nov; 22(11):1155-72; quiz 1173-4. PubMed ID: 26382310
[TBL] [Abstract][Full Text] [Related]
2. The 2023 nonhormone therapy position statement of The North American Menopause Society.
“The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2023 Jun; 30(6):573-590. PubMed ID: 37252752
[TBL] [Abstract][Full Text] [Related]
3. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
Umland EM
J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
[TBL] [Abstract][Full Text] [Related]
5. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
6. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
Thacker HL
J Womens Health (Larchmt); 2011 Jul; 20(7):1007-16. PubMed ID: 21675874
[TBL] [Abstract][Full Text] [Related]
7. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
8. Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA; Crider M; Hill SR
Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
[TBL] [Abstract][Full Text] [Related]
9. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
10. Hormonal and nonhormonal treatment of vasomotor symptoms.
Krause MS; Nakajima ST
Obstet Gynecol Clin North Am; 2015 Mar; 42(1):163-79. PubMed ID: 25681847
[TBL] [Abstract][Full Text] [Related]
11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
12. Symptoms of menopause: hot flushes.
Santoro N
Clin Obstet Gynecol; 2008 Sep; 51(3):539-48. PubMed ID: 18677148
[TBL] [Abstract][Full Text] [Related]
13. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Alexander IM; Moore A
J Am Acad Nurse Pract; 2007 Mar; 19(3):152-63. PubMed ID: 17341283
[TBL] [Abstract][Full Text] [Related]
14. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).
North American Menopause Society
Menopause; 2011 Jul; 18(7):732-53. PubMed ID: 21685820
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.
Umland EM; Falconieri L
Int J Womens Health; 2012; 4():305-19. PubMed ID: 22870045
[TBL] [Abstract][Full Text] [Related]
16. Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
Carroll DG; Lisenby KM; Carter TL
Int J Womens Health; 2015; 7():615-24. PubMed ID: 26124682
[TBL] [Abstract][Full Text] [Related]
17. Beyond Estrogen: Treatment Options for Hot Flashes.
McGarry K; Geary M; Gopinath V
Clin Ther; 2018 Oct; 40(10):1778-1786. PubMed ID: 30217591
[TBL] [Abstract][Full Text] [Related]
18. Topical, geospatial, and temporal diffusion of the 2015 North American Menopause Society position statement on nonhormonal management of vasomotor symptoms.
Carpenter JS; Laine T; Harrison B; LePage M; Pierce T; Hoteling N; Börner K
Menopause; 2017 Oct; 24(10):1154-1159. PubMed ID: 28538600
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
Weber L; Thacker HL
Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
[TBL] [Abstract][Full Text] [Related]
20. The 2022 hormone therapy position statement of The North American Menopause Society.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2022 Jul; 29(7):767-794. PubMed ID: 35797481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
